United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corp. Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options on October 29, 2026, at $117.76 per share, acquiring 9,500 common shares; family trusts also sold 9,500 common shares that day under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The sale entries report per-share prices of $590.4296 (53 shares), $591.9020 (1,104), $592.9686 (1,563), $593.8794 (1,540), $594.8947 (1,248), $595.8794 (1,678), $596.8608 (1,355), $597.6552 (919), and $599.30 (40). For multiple-trade batches with price footnotes, the reported prices are weighted averages. The option position after the exercise was 128,910 options.
United Therapeutics Corp. (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options at $117.76 per share on October 28, 2026, acquiring 9,500 common shares. The reported post-exercise option position was 138,410 options. The trust sold 9,500 shares in six transactions at weighted-average prices from $583.5017 to $588.3913 per share, under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported the exercise of 9,500 options held in a family trust at $117.76 per share, acquiring 9,500 common shares on October 27, 2026. Trust-held shares were sold at reported weighted-average prices from $582.6649 to $592.8350 per share.
The exercise and sales were under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025. It continues until the earlier of exercise of 1,734,410 options, all expiring March 15, 2027, or December 31, 2026. The reported option balance afterward was 147,910.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options on October 26, 2026, at $117.7600 per share, resulting in 9,500 common shares. The resulting shares were sold through family trusts in eight reported transactions, including a 600-share sale at a weighted-average price of $585.7122 per share and an 806-share sale at $592.9168 per share. The exercise and sales were under a pre-arranged Rule 10b5-1 plan adopted November 7, 2025; the reported option position following the exercise was 157,410.
United Therapeutics' Chairperson & CEO, Martine A. Rothblatt, reported that a family trust in which she shares investment power exercised 9,500 stock options at $117.76 per share on October 23, 2026, and family trusts sold the resulting 9,500 common shares in 11 reported transactions. The sale prices were reported as weighted averages ranging from $577.6774 to $587.9997 per share. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The trust's reported option balance following exercise was 166,910 stock options.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options for 9,500 common shares at an exercise price of $117.76 on October 22, 2026; family trusts sold 9,500 resulting shares that day. Reported per-share prices across the sale entries ranged from $562.9700 to $590.3970.
The exercise and sales were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The reported post-transaction stock-option position was 176,410 options. Separate holdings entries list 40,513 directly held common shares and 166 shares held by her spouse.
United Therapeutics Corp. (UTHR) reported that Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options on October 21, 2026, at $117.76 per share. The resulting 9,500 shares held through family trusts were sold that day. The exercise and sales were made under a pre-arranged 10b5-1 trading plan adopted November 7, 2025. After the exercise, 185,910 stock options were reported as held through a family trust.
United Therapeutics Corporation’s board approved a new authorization for the company to repurchase up to $2 billion of its common stock. The authorization is available for a one-year period ending October 21, 2027.
The company may use accelerated share repurchases, open market transactions, privately negotiated transactions or other means. Purchases are discretionary, with no minimum number of shares required, and the company may start or suspend them at any time without prior notice. A separate accelerated share repurchase transaction entered into in September 2026 under the prior authorization is scheduled to terminate in the fourth quarter of 2026, subject to earlier termination or extension under its terms; it will not reduce the amount available under the new authorization.
United Therapeutics (UTHR) Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options at $117.76 per share on October 20, 2026; the resulting 9,500 common shares were sold in 17 transactions through family trusts. The exercise and sales were pursuant to a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The report lists 195,410 stock options following the exercise.
United Therapeutics Chairperson & CEO Martine A. Rothblatt reported that a family trust exercised 9,500 stock options on October 19, 2026, at $117.76 per share and acquired 9,500 common shares; the trust also sold 9,500 shares at reported weighted-average prices ranging from $534.7498 to $556.8750 per share. The exercise and sale were pursuant to a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025. The reported post-exercise option position was 204,910 options.